
<div class="notifyMain">
  <div class="notifyMain-inner">
    <div class="notifyMain-content">
      <h2 class="notifyMain-heading">Indication and Limitation of use</h2>
      <div class="notifyMain-copy">
        <p>Vectibix® is indicated for the treatment of patients with wild‑type RAS metastatic colorectal cancer (mCRC). Wild‑type RAS is defined as wild‑type in both KRAS and NRAS as determined by an FDA‑approved test for this use: </p>
        <ul>
          <li>As first‑line therapy in combination with FOLFOX  </li>
          <li>As monotherapy following disease progression after prior treatment with fluoropyrimidine‑, oxaliplatin‑, an  irinotecan‑containing chemotherapy </li>
        </ul>
        <p>Limitation of Use: Vectibix<sup>&reg;</sup>is not indicated for the treatment of patients with RAS‑mutant mCRC or for whom RAS mutation status is unknown.  </p>
      </div>
    </div>
    <div class="notifyMain-close"></div>
  </div>
</div>